论文信息 - Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. - 字舞流文

Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.

L. Lipton | J. Desai | A. Scott | B. Solomon | I. Davis | R. Hicks | P. Clemens | Jong-Soon Park | F. Finckenstein | T. A. Gestone | Jong‐Soon Park